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Abstract 
Using the plaque reduction assay, relatively simple bicyclic quinone molecules, as well as 
multiple copies thereof covalently attached to a long polyglutamate-based polymeric chain, were 
examined as new inhibitors of various naturally occurring strains of influenza A virus. The 
polymer-conjugated inhibitors were found to have a far greater potency (for some as high as two 
orders of magnitude when a long spacer arm was employed) than their corresponding parent 
molecules against the human Wuhan influenza strain. However, such polymeric inhibitors failed 
to exhibit higher potency compared to their small-molecule predecessors against the human 
Puerto Rico and avian turkey influenza strains. These observations, further explored by means of 
molecular modeling, reveal the previously unrecognized unpredictability of the benefits of 
multivalency, possibly because of poor accessibility of the viral targets to polymeric agents.   
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Introduction 
Influenza A virus is highly transmissible and kills over 250,000 people worldwide each 
year. In the United States alone, some 20% of the population contracts the virus annually leading 
to countless missed days of work and school and tens of billions of dollars in associated costs.1, 2 
The two FDA-approved drugs for the treatment of influenza infections, Oseltamivir (Tamiflu™) 
and Zanamivir (Relenza™), have fallen short of expectations due to their mediocre activity in 
reducing the symptoms and duration of the infection, as well as emerging resistance in clinical 
isolates.3, 4, 5 Thus new, more effective anti-influenza therapeutic agents are greatly needed.  
 One proposed strategy for generating more potent inhibitors of influenza is to utilize the 
benefits of multivalency.2, 4, 6-11 Conjugating multiple copies of influenza inhibitors to a flexible 
polymeric chain has been shown to result in multivalent interactions between the polymer-
attached inhibitors and the viral surface receptor proteins.2, 4, 6-11 These enhanced interactions, in 
turn, lead to a much stronger binding compared to that of the small-molecule parents stemming 
from favorable entropic factors; additionally, water-swollen polymeric chains may sterically 
hinder physical contacts between the virus and the target cell.6  
 The foregoing benefits of multivalency for binding to influenza virus have been 
demonstrated for viral surface proteins with the natural ligand of hemagglutinin, N-
acetylneuraminic (sialic) acid, and with the neuraminidase inhibitor Zanamivir.2, 4, 6-11 However, 
both of these compounds are structurally complex requiring many-step syntheses to become 
amenable to attachment to polymeric chains in order to investigate the effect of multivalency.2, 4 
They are also difficult to modify selectively and thus not optimal for structure-activity 
relationship (SAR) studies. In the present work, we instead have employed simple organic 
molecules12 with anti-influenza properties to investigate the SAR of multivalency. In particular, 
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we have assessed whether the aforementioned potential benefits of multivalency invariably 
translate into greater anti-influenza activity. 
 
Materials and Methods 
Materials  
All small-molecule inhibitors except for 13 (Figure 1), poly-L-glutamate Na salt (50 -100 
kDa), solvents, and reagents were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO) 
and used without further purification. Dialysis membranes (3,500 kDa molecular weight cutoff) 
were from Spectrum Labs (Rancho Dominguez, CA) and PD-10 desalting columns from GE 
Healthcare (Buckinghamshire, U.K.). 
 
Syntheses 
 Synthesis of 6-(hydroxymethyl)naphthalene-1,4-dione (13) was carried out as described 
by Antonini et al.13 
Synthesis of 2a, 2b, 5a, 5b, 8, 11, and 14: Conjugation was carried out via a Steglich 
esterification with minor deviations from a reported procedure.14 Specifically, poly-L-glutamate 
Na salt was converted to poly(L-glutamic acid) by dissolution in double-distilled (dd) H2O, 
lowering the pH to 1, and washing with 0.10 M HCl to remove free salts before an overnight 
lyophilization. Lyophilized poly(L-glutamic acid) (20 mg, 0.16 mmol) was dissolved in 0.80 mL 
of dry dimethylformamide (DMF), followed by the addition of N,N′-dicyclohexylcarbodiimide 
(DCC) (4.3 mg (0.021 mmol) in 0.30 mL of DMF for a ~10% derivatization), an anti-influenza 
agent (0.050 mmol in 0.20 mL of DMF), pyridine (10 µL, 0.12 mmol), and a catalytic quantity of 
4-dimethylaminopyridine (DMAP) in 0.40 mL of DMF with vigorous stirring. The solution was 
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stirred overnight at room temperature. The polymer was then isolated by precipitation in 
chloroform, washed with fresh chloroform to remove the unreacted anti-influenza agent, 
converted to the Na salt, and dialyzed against ddH2O in a 3,500-Da MW cutoff dialysis 
membrane for 24 hr to remove free salts and other impurities. TLC using a 3:1 (v/v) ethyl 
acetate:hexanes mixture confirmed purity and demonstrated the disappearance of the anti-
influenza agent’s spot. Percent conjugation of the anti-influenza agent was calculated by means 
of 1H-NMR in D2O using a Bruker 600 MHz instrument by comparing the ratio of the integration 
of a polymer peak with that of an anti-influenza agent’s peak. In the case of a ~5% derivatization 
of the polymer with anti-influenza agent, 2.0 mg/0.010 mmol of DCC was added to the reaction 
mixture (2b, 5b, and 11).  
1H-NMR (D2O) δ (600 MHz) — for 2a and 2b: 1.6-2.0 (2H polymer, d, CH2), 2.1-2.5 
(2H polymer, s, CH2), 4.0-4.4 (1H polymer, s, CH), 6.8-8.0 (5H, aromatics); for 5a and 5b: 1.8-
2.1 (2H polymer, d, CH2), 2.1 (2H, m, cyclohexyl CH2), 2.2-2.4 (2H polymer, s, CH2), 2.6 (2H, 
m, cyclohexyl CH2), 2.8 (2H, m, cyclohexyl CH2), 4.2-4.4 (1H polymer, s, CH), 7.3-7.9 (3H, 
aromatics); for 8: 1.6-2.0 (2H polymer, d, CH2, 3H, s, CH3), 2.1-2.5 (2H polymer, s, CH2), 4.0-
4.4 (1H polymer, s, CH), 7.5-8.0 (4H, aromatics); for 11: 1.9-2.2 (2H polymer, d, CH2), 2.3 (3H, 
s, CH3), 2.4-2.5 (2H polymer, s, CH2), 4.0-4.4 (1H polymer, s, CH), 6.9-8.2 (4H, aromatics); for 
14: 1.6-2.0 (2H polymer, d, CH2), 2.0 (2H, s, CH2), 2.0-2.3 (2H polymer, s, CH2), 4.0-4.4 (1H 
polymer, s, CH), 6.7-8.0 (4H, aromatics).  
 Synthesis of 3, 6, 9, and 12: The conjugation of the anti-influenza agents to the polymer 
through a spacer arm was carried out via a Cu+-catalyzed [3+2] azide-alkyne cycloaddition in 
three steps. First, poly-L-glutamate Na salt was derivatized with propargylamine as described by 
Ochs et al.15 Next, anti-influenza agents were derivatized with a linker terminating with an azide 
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to be used in the subsequent cycloaddition. To this end, anti-influenza agent (0.30 mmol) was 
dissolved in 8 mL of dry dichloromethane, followed by the addition of azidopentanoic acid (50 
µL, 0.40 mmol), N,N'-diisopropylcarbodiimide (DIC) (60 µL, 0.40 mmol), pyridine (50 µL, 0.60 
mmol), and a catalytic quantity of DMAP. The reaction mixture was stirred overnight, 
concentrated by rotary evaporation, and purified by column chromatography (2:1 (v/v) 
hexanes:ethyl acetate) to generate such compounds as 15. For the conjugation of anti-influenza 
agents to the polymer via cycloaddition, the alkyne-derivatized poly-L-glutamate Na salt (68 mg, 
0.45 mmol) was dissolved in 1.5 mL of ddH2O. The above-mentioned purified linker-derivatized 
anti-influenza agent (0.10 mmol) was dissolved in 1.5 mL of tert-butanol and added to the 
water/polymer mixture. A 1.0 M aqueous solution of Na ascorbate (75 µL) and a 0.10 M aqueous 
solution of CuSO4 (50 µL) were then added; the reaction mixture was incubated overnight,16 
concentrated via rotary evaporation, dissolved in phosphate buffered saline (PBS), run on a PD-
10 desalting column, and dialyzed as above to remove unreacted starting material and reagents. 
Polymer conjugates were analyzed as outlined above to quantify derivatization.  
1H-NMR (D2O) δ (600 MHz) — for 3: 1.5 (2H, m, CH2), 1.7-2.1 (2H polymer, d, CH2, 
4H, m, CH2), 2.1-2.5 (2H polymer, s, CH2), 4.0-4.5 (1H polymer, s, CH, 4H, m, CH2), 6.8-8.0 
(6H, aromatics); for 6: 1.7 (2H, m, CH2), 1.8-2.1 (2H polymer, d, CH2, 4H, m, CH2), 2.1 (2H, m, 
cyclohexyl CH2), 2.1-2.5 (2H polymer, s, CH2), 2.6 (2H, m, cyclohexyl CH2), 2.7 (2H, m, 
cyclohexyl CH2), 4.2-4.5 (1H polymer, s, CH, 4H, m, CH2), 7.2-8.0 (4H, aromatics); for 9: 1.5 
(2H, m, CH2), 1.7-2.1 (2H polymer, d, CH2, 4H, m, CH2, 3H, s, CH3), 2.1-2.5 (2H polymer, s, 
CH2), 4.2-4.5 (1H polymer, s, CH, 4H, m, CH2), 7.4-8.1 (4H, aromatics); for 12: 1.6 (2H, m, 
CH2), 1.7-2.1 (2H polymer, d, CH2, 4H, m, CH2, 3H, s, CH3), 2.1-2.5 (2H polymer, s, CH2), 4.2-
4.5 (1H polymer, s, CH, 4H, m, CH2), 6.5-8.0 (5H, aromatics). 
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 Synthesis of 1-(5-((6-methyl-5,8-dioxo-5,8-dihydronaphthalen-1-yl)oxy)-5-oxopentyl)-
1H-1,2,3-triazol-4-yl)methanaminium (16) was carried out similarly to the aforementioned 
cycloaddition. Briefly, 6-methyl-5,8-dioxo-5,8-dihydronaphthalen-1-yl 5-azidopentanoate (15) 
(33 mg, 0.10 mmol) was dissolved in 1.5 mL of tert-butanol. To that mixture, propargylamine 
(6.0 µL, 0.10 mmol) in 1.5 mL of ddH2O was added, followed by the addition of a 1.0 M 
aqueous solution of Na ascorbate (75 µL) and a 0.10 M aqueous solution of CuSO4 (50 µL). The 
reaction was stirred overnight, concentrated by rotary evaporation, and dissolved in ddH2O. 
Following the addition of chloroform the aqueous fraction was recovered, dissolved in methanol, 
filtered, and concentrated for characterization by 1H-NMR and for further use in biological 
assays.  
1H-NMR (MeOD) δ (400 MHz) for 16: 1.6 (2H, m, CH2), 2.0 (2H, m, CH2, 3H, s, CH3), 
2.7 (2H, m, CH2), 4.1 (2H, m, CH2), 4.4 (2H, m, CH2), 6.6 (1H, s, H3 aromatic), 7.3 (1H, d, H8 
aromatic), 7.7 (1H, dd, H7 aromatic), 7.9 (1H, d, H6 aromatic), 8.1 (1H, s, NCHC). 
 Synthesis of 17 and 18: For 17, poly-L-glutamate Na salt was activated with 
propargylamine as described above and then the remaining carboxylates were converted to their 
free acids by reducing the pH, followed by the removal of water by freeze-drying. The resultant 
compound (40 mg) was dissolved in 1.5 mL of DMF, then N-hydroxysuccinimide (NHS) (79 
mg, 0.69 mmol) was added with stirring, and the temperature was reduced to 0 ºC, followed by 
an addition of DIC (108 µL, 0.69 mmol). The reaction mixture was stirred on ice for 30 min and 
at room temperature for 3 hr, after which time an excess of aqueous NH4OH was added to 
displace the NHS-ester moieties resulting in a neutral poly-L-glutamine.4, 17 Conjugation of 15 to 
the propargylamine-derivatized poly-L-glutamine was carried out via a cycloaddition as 
described above. For 18, poly-L-glutamate Na salt was derivatized with propargylamine in the 
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same way as above, except that an excess of propargylamine (30 µL, 0.47 mmol) was added. For 
derivatization with inhibitor, the reaction was run as above, but only 0.1 mole-equivalents of 15 
was used.  
1H-NMR (D2O) δ (600 MHz) — for 17: 1.6 (2H, m, CH2), 1.8-2.2 (2H polymer, d, CH2, 
4H, m, CH2, 3H, s, CH3), 2.2-2.4 (2H polymer, s, CH2), 4.2-4.5 (1H polymer, s, CH, 4H, m, 
CH2), 6.4-8.0 (5H, aromatics); for 18: 1.6 (2H, m, CH2), 1.9-2.2 (2H polymer, d, CH2, 4H, m, 
CH2, 3H, s, CH3), 2.2-2.5 (2H polymer, s, CH2), 2.6 (1H, s, CH), 3.9 (2H, s, CH2), 4.2-4.5 (1H 
polymer, s, CH, 4H, m, CH2), 6.3-7.9 (5H, aromatics). 
 
Cells, Viruses, and Antiviral Assays 
 Madin-Darby canine kidney (MDCK) cells were purchased from the American Type 
Culture Collection (ATCC) and maintained as described by Haldar et al.2 The wild-type 
influenza A viruses Wuhan/359/95 (Wuhan) (H3N2) and turkey/MN/833/80 (turkey) (H4N2) 
were obtained from the U.S. Centers for Disease Control and Prevention (CDC), and the 
influenza A strain PR/8/34 (Puerto Rico) (H1N1) was purchased from Charles River 
Laboratories (North Franklin, CT). The viruses were stored at -80ºC and diluted in PBS prior to 
assays. 
 Plaque reduction assays with MDCK cells were conducted to determine the half-maximal 
inhibitory concentration (IC50 value) for each compound tested using a literature methodology.2, 4 
For plaque reduction assays investigating the effect of inhibitor in the solid growth agar, equal 
concentrations of the inhibitor were used during pre-incubation, infection, and in the nutrient 
agar formulation.   
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Docking simulations   
 The hemagglutinin structures of the Puerto Rico and X-31 strains of influenza A virus 
were obtained from the Protein Data Bank (PDB: 1RU7 and 2HMG, respectively). The docking 
studies for the hemagglutinin proteins and compounds 10 and 16 were performed with AutoDock 
Vina18 and AutoDock Tools interface. All rotatable bonds in the ligands were allowed to rotate 
freely using the default settings. The search area, selected based on the previous studies with 
influenza small-molecule hemagglutinin inhibitors,12, 19 covered the majority of the grooves of 
the protein. The final results were selected based on the best binding modes.  
 
 
Results and Discussion 
 Since the inherent structural complexities of Zanamivir and sialic acid do not allow for 
easy manipulations, for our SAR studies we chose to investigate whether there were simpler 
molecules also possessing anti-influenza activity. In the scholarly study by Bodian et al.,12 
expanded by others,19 docking simulations were performed to discover small organic molecules 
that bind to the hemagglutinin protein on influenza A viral strain X31 (H3N2) and stabilize the 
protein in its native conformation. This stabilization was proposed to hinder the conformational 
changes necessary for cell-viral membrane fusion, which is an essential step in the influenza 
infection cycle.12 Specifically, the binding site explored was a region approximately half-way 
between the most outer tip of the hemagglutinin protein and the viral membrane near the fusion 
peptide.12 These docking studies resulted in a group of benzoquinones and hydroquinones as 
potential ligands to bind to hemagglutinin and to inhibit the aforementioned conformational 
change.12  
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One of the foregoing compounds, 5-hydroxynaphthalene-1,4-dione (1), was selected as a 
starting point for our studies. Using the plaque reduction assay method to test 1 for putative anti-
influenza activity against the Wuhan strain of the influenza A virus, we indeed found it to be a 
moderate inhibitor with an IC50 value of 4.7 ± 1.5 µM (Table 1, 1st entry). While other unnatural 
anti-hemagglutinin inhibitors exist (figure 2),20-25 all are structurally more complex than 1. 
Therefore, we decided to continue our studies herein with compound 1. 
In light of the previous studies with polymer-attached Zanamivir and sialic acid,2, 4, 6-11  
we next tested whether covalent conjugation of multiple copies of 1 to a polymeric chain would 
increase anti-influenza potency.  To this end, 1 was attached to the physiologically benign and 
biodegradable polymer poly-L-glutamate at a ~10% loading (i.e., with approximately one tenth 
of all monomeric units being derivatized with the inhibitor). The resultant polymeric inhibitor 2a 
exhibited an over 10-fold better IC50 value compared to its monomeric counterpart 1 (Table 1, 
2nd entry), presumably due to the phenomenon of multivalency. Interestingly, lowering the 
degree of loading of the inhibitor on the polymer from 10% to 5% (to yield 2b) failed to improve 
the antiviral potency (Table 1), suggesting that the polymer-conjugated ligand molecules do not 
interfere with each other’s ability to inhibit the virus.  
One can readily envisage how steric constraints imposed by the polymeric chain may 
hinder the ability of the inhibitor to bind to its viral receptor, thus masking the true power of 
multivalency. This hypothesis was verified by inserting a nine-atom spacer arm between the 
polymer and 1, resulting in compound 3. As seen in Table 1, this insertion indeed dramatically 
improved the IC50 value: 20-fold over 2a and some 240-fold over 1.  
To examine the generality of these findings, several structural analogs of 1, not 
previously identified as anti-influenza inhibitors,12 were tested, along with their synthesized 
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poly-L-glutamate conjugates, against the Wuhan influenza strain.  5-Hydroxy-3,4-
dihydronaphthalene-1(2H)-one (4) and 2-hydroxy-3-methylnaphthalene-1,4-dione (7) both were 
found to be inhibitors, albeit much weaker ones than 1. Conjugating them to the polymer 
directly, i.e., with no spacer arm (to produce 5a or 5b depending on the degree of loading and 8, 
respectively) led to marked (7 and >3 fold, respectively) improvements in the antiviral potency 
(Table 1). Moreover, as seen in Table 1, when the nine-atom spacer arm was inserted to further 
distance the ligand from the polymeric chain (to form 6 and 9, respectively), the inhibitory 
potency in both cases rose another several-fold to reach the overall improvement compared to 
those of the parents 4 and 7 of 38 fold and >140 fold, respectively.  
The same general trend of a dramatically enhanced inhibitory potency upon attachment to 
the polymeric chain via the spacer arm was observed with yet another analog of 1 tested, namely 
5-hydroxy-2-methyl-1,4-naphthalenedione (10). This compound, which differs from 1 only by a 
methyl substituent in the benzoquinone portion of the molecule, exhibited an IC50 value 
comparable to that of 1; converting it to 12 produced a 52-fold jump in inhibitory activity (Table 
1). Interestingly, however, in the case of 10 attached to the polymer with no spacer arm (11), no 
increase (and, in fact, a sizeable decline) in the potency was observed (Table 1), illustrating how 
subtle the SAR is.  
The poly-L-glutamate conjugate of 13 (in the absence of a nine-atom linker), 14, 
exhibited a greater than 30-fold improvement over its monomeric counterpart (Table 1) 
demonstrating that attachment through the 6C position in the naphthoquinone moiety does not 
have a deleterious effect on the inhibitor improvement; in fact, it generated the most potent non-
linker conjugated inhibitor.  
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In addition to a striking improvement in the inhibitory potency of the ligands upon 
conjugating them to poly-L-glutamate via the long spacer arm, their toxicity also diminished. In 
particular, both for 2a, 2b, and 3 vs. 1 and for 11 and 12 vs. 10 the cellular toxicity was at least 
an order of magnitude lower. For example, when compound 1 was used in the infection phase of 
the plaque reduction assay, cells that were incubated with the concentrations of inhibitor greater 
than, or equal to, 30 µM displayed obvious fatal demise. In contrast, cells incubated with even 
greater than 300 µM concentrations of polymer-attached inhibitors 2a, 2b, and 3 were healthy 
and seemingly unaffected by the presence of inhibitor. Presumably, sequestering the toxic small 
molecules (50% cell cytotoxicity concentration, CC50, of ~30 µM for 112) to the polymer 
prevents them from traversing the cellular membrane and exerting deleterious effects within the 
cell.  
To determine to what extent the foregoing findings apply to other influenza A viruses, we 
selected two additional strains, namely the avian turkey and the human Puerto Rico ones. Both 
strains have different serotypes of the hemagglutinin and neuraminidase proteins compared to 
Wuhan’s, leading to subtle differences in the amino acid makeup and structure of these 
proteins.26 Using the plaque reduction assay, we tested the monomeric inhibitors 1, 7, 10, and 13, 
as well as those attached to poly-L-glutamate either via the nine-atom spacer arm (compounds 3, 
6, and 12) or directly (14). As in the case of the Wuhan strain, 1, 10, and 13 were substantial 
inhibitors of the viruses, whereas 7 was not (Table 2), suggesting similarities in the receptors’ 
binding sites of all three strains.  And yet, in stark contrast to the observations made with the 
Wuhan strain (Table 1), conjugation to the polymeric chains even via a long spacer arm not only 
failed to result in a significant improvement of the anti-influenza potency but, in the case of 1 
and 10, actually made it markedly worse, i.e., increased the IC50 values (Table 2).  For 14, 
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conjugation of the inhibitor to the polymer though the C6 position in the naphthoquinone also 
caused a substantial deterioration in potency for both turkey and Puerto Rico strains suggesting 
that the site of the linker’s attachment is not entirely responsible for the reduction in inhibition. 
We hypothesized that perhaps the addition of the linker group itself imposed new steric 
hindrances for binding of the inhibitor to the receptor sites on the turkey and Puerto Rico, but not 
the Wuhan, strains of the virus. This would inevitably lead to a diminished ability of the inhibitor 
to bind to its receptor when subsequently attached to poly-L-glutamate. To test this hypothesis, 
we focused on the compound 10 group of inhibitors and synthesized compound 16 containing the 
same chemical structure as the inhibitor plus the spacer arm portion of 12 but in the absence of 
polymer. As seen in Table 3, 16 indeed exhibited a drastically poorer anti-influenza inhibition 
against all three viruses compared to the parent compound 10.    
Thus the deteriorated inhibition potency upon attachment of the nine-atom spacer arm 
indeed may account for at least some of the inferior inhibition observed for compounds 3, 9, and 
12 compared to their monomeric precursors 1, 7, and 10, respectively, against the turkey and 
Puerto Rico strains. However, in order for 12 to exhibit the multivalency benefits over 16 of 
greater than 100 fold (as it did with Wuhan strain, Table 3), the IC50 value of 16 would have to 
be at least 104 µM for the Puerto Rico and turkey strains. The results of the plaque reduction 
assay suggest that this is not the case though: a reduction in plaque numbers for both of these 
strains upon incubation with 90 µM 16 indicated that the IC50 was close to 100 µM (data not 
shown). The exact IC50 for 16 was not measurable however, due to cytotoxicity of the 
compound. 
Next we investigated the role of the polymer’s charge in antiviral activity. To this end, 
two new polymer conjugates with compound 10 attached via the nine-atom spacer arm (17 and 
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18) were prepared and tested against the Wuhan and turkey strains. Compound 17, containing a 
neutral poly-L-glutamine backbone, showed modest improvements for the turkey strain over its 
negatively charged analog 12 but failed to exhibit a great enhancement over the monomer 10 
(Table 4). Conversely, for the Wuhan strain, 17 demonstrated an almost 50-fold improvement 
over the monomer, similar to that afforded by compound 12 (Table 4). Likewise, compound 18 
(containing a partly negatively charged backbone) displayed no great enhancement for the turkey 
strain while exhibiting an almost 40-fold improvement over 10 for the Wuhan strain. These 
results indicate that the charge on the polymeric chain cannot account for the striking differences 
observed between the turkey and Wuhan strains for monomeric vs. polymer-attached inhibitors.  
To determine whether the difference in improvements for polymer-attached conjugates 
over monomeric inhibitors between the Wuhan and turkey strains was an artifact of our 
biological assay, i.e., whether the inhibitor was brought into contact with the virus at the 
inappropriate time during infection, we performed an additional plaque assay with 10 and 12 
present not only during the pre-incubation and binding (as is conventionally done) but also with 
the inhibitor in the agar overlay. This modality of the plaque reduction assay exposes cells and 
viruses to the inhibitor for the entirety of the first and subsequent infection phases leaving the 
inhibitor available for all steps in the viral cycle and not just for binding or endocytosis. In this 
experimental mode, the inhibitory effect of 10 and 12 for the Wuhan strain changed only 
modestly: IC50’s of 2.4 ± 0.39 µM and 0.061 ± 0.045 µM, respectively, for incubation of 
inhibitor in the agar overlay vs. 5.7 ± 1.7 µM and 0.11 ± 0.070 µM for our conventional 
experiment. For the turkey strain, the inhibition by the monomer (10) improved more (IC50 of 17 
± 1.0 µM when not included in the agar and 2.9 ± 0.49 µM when included in the agar) but the 
polymer-attached inhibitor’s (12’s) IC50 exceeded 5 µM; these observations confirm that the lack 
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of improvement for polymer-attached inhibitors against the turkey strain was not an artifact of 
our biological assay.  
We then hypothesized that the preferred binding sites of the monomeric vs. the polymer-
attached inhibitors might be distinct between the strains, thus being responsible for their vastly 
different inhibitory properties. To explore this possibility, we ran in silico docking experiments 
to determine the preferred binding sites for the monomeric inhibitor 10 and the linker-attached 
inhibitor 16 for the Puerto Rico strain and a Wuhan surrogate strain, X-31 (both H3N2). Note 
that the X-31 strain has a 87% sequence identity for the HA1 strand of the hemagglutinin 
molecule compared to the Wuhan strain (the HA2 Wuhan sequence is unavailable)27, 28 (for 
comparison, the Puerto Rico’s HA1 strand has just a 33% sequence identity29). As seen in Figure 
4A, for the X-31 strain both inhibitors bind in the same region of the hemagglutinin protein; this 
region coincides with the crystallographically determined binding site for tert-butyl 
hydroquinone (another fusion inhibitor described by Bodian et al.12, 19). In stark contrast, for the 
Puerto Rico strain, inhibitors 10 and 16 bind in vastly distinct locations on the hemagglutinin 
protein, with as much as 40 Å separating them (Fig. 4B). Note that 10 binds to a similar location 
on the Puerto Rico strain’s hemagglutinin as both 10 and 16 in the X-31’s protein; however, 16 
on the Puerto Rico strain’s hemagglutinin binds in a region that is closer to the viral envelope, 
thereby possibly hindering accessibility for the polymer-attached inhibitor.  
One has to wonder why there are benefits of multivalency for all the compounds tested 
attached via a long spacer arm to a poly-L-glutamate for one strain of influenza, but not for the 
other two (Tables 1 and 2). It is unlikely that the observed differences in inhibition among viral 
strains are due to dissimilar spacing of hemagglutinin molecules along the viral surface among 
different strains. There ~400 hemagglutinin molecules on a given viral particle of roughly the 
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same size regardless of the influenza virus strain.  Since the mechanism of viral particle 
formation is the same for different strains, the spacing among hemagglutinin molecules on 
average should be similar as well.26 The binding of the first polymer-attached inhibitor molecule 
to hemagglutinin is also unlikely to prevent binding of all the others. Although the binding of the 
first inhibitor molecule indeed might make it sterically impossible for a second, nearby counterpart to 
bind to hemagglutinin, that cannot be the case for more distant polymer-attached inhibitor molecules. 
Since our (~10%-derivatized) polymeric chain contains some 50 randomly distributed inhibitor 
molecules, most of them should be sufficiently remote from the first one bound to interact with another 
hemagglutinin molecule.  
The three influenza strains undoubtedly have some differences in the binding site for 
these inhibitors;26 in the case of the turkey and Puerto Rico strains, these differences might 
interplay with the polymer and/or linker deleteriously to weaken the binding of the conjugated 
inhibitor to the virus. Additionally, the topology of the viral surface might introduce accessibility 
problems for the inhibitors once they are attached to the bulky, hydrated polymeric chain. In 
previous studies of the effect of multivalency on anti-influenza inhibitors, the receptor of the 
multivalent ligand was proximal to the solvent-exposed outer edge of the surface protein.2, 4, 6-11 
Although the exact location of binding of 1 and its analogs to hemagglutinins in the strains 
studied herein is unknown, our docking studies (Fig. 4) predict that for 10 and 16 the site is 
located approximately half-way down the protein for the X-31 strain and close to the viral 
envelope for the linker-attached inhibitor (16) on the Puerto Rico strain.12 Perhaps while a small 
molecule readily accesses regions down the stock of the protein, conjugation to a bulky 
polymeric chain hampers the access below the dense canopy of proteins on the viral surface. 
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The concept of multivalency stipulates that several simultaneous interactions of ligands 
and receptors should result in a stronger, multipoint inhibitor-virus binding and hence give rise to 
more potent inhibitors (Figure 5).6 Our results herein suggest, however, that this is indeed the 
case only if attaching an inhibitor to a polymeric chain does not impose negative spatial 
constraints not outweighed by the inherent benefits of multivalency. Since it is unknown in 
advance whether this will be the case, our data illustrate that the superiority of multivalent 
inhibitors of a virus compared to their monovalent predecessors cannot be automatically 
assumed. 
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Figure Legends 
 Figure 1. Chemical structures of (A) 5-hydroxynaphthalene-1,4-dione (1) and its analogs 
4, 7, 10, and 13 used in this study; (B) modified 10 with an azide-terminated spacer arm (15) for 
use in conjugating to propargylamine-derivatized poly-L-glutamate and 10 derivatized with a 
spacer arm (16) for investigation of the dependence of IC50 on the presence of the spacer arm by 
itself with no polymer. 
 Figure 2. Chemical structures of anti-hemagglutinin agents previously described in the 
literature: (A) Neu5Ac3αF-DSPE; 20 (B) N-(2,8-dimethyl-3-oxo-1-thia-4-azaspiro[4.5]decan-4-yl)-6-
methylimidazo[2,1-b]thiazole-5-carboxamide; 21 (C) 4-amino-5-chloro-2-hydroxy-N-((2S,6R,9aR)-6-
methyloctahydro-1H-quinolizin-2-yl)benzamide; 22 (D) N-(3-cyanophenyl)-N-methyl-2-
phenylcyclohexanecarboxamide; 23 (E)	  methyl-O-methyl-7-ketopodocarpate; 24 (F) 3-fluoro-N-(2-
(piperidin-1-yl)ethyl)-5-(trifluoromethyl)benzamide 25 . It is worth noting that 1 is a more potent anti-
influenza inhibitor than compound F (IC50 of 315 µM),25 on par with compounds A, B, and C 
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(IC50’s of 5.6, 3-23, and 3-8 µM, respectively),20-22 and less potent than compounds D and E 
(IC50’s of 98 and 31 nM, respectively).23,24 
 Figure 3. Chemical structures of anti-influenza inhibitors attached to poly-L-glutamate 
(A) with no spacer arm; (B) via a nine-atom spacer arm intended to reduce the putative steric 
hindrances imposed by the polymeric chains; (C) with the polymeric backbone of varying 
degrees of electrostatic charge.   
 Figure 4. The docking results for inhibitors 10 and 16 (both black) on the hemagglutinin 
protein (grey) of the X-31 strain (a surrogate used to represent the Wuhan strain) (A, left panel) 
and of the Puerto Rico strain (B, right panel) of influenza A virus. As seen in A, the binding sites 
on the protein for the two inhibitors overlap in the former case. In contrast, the distance between 
the binding sites for the two inhibitors in B is some 40 Å indicating that the molecules bind to 
the protein in vastly distinct locations. The images, generated in Pymol, depict only 10 and 16 
docked on one hemagglutinin monomer for each viral strain. 
 Figure 5. A cartoon depicting a multivalent vs. a monovalent interaction of an inhibitor 
with the virus. The top panel (A) depicts a polymer-attached inhibitor (polymer is black line, 
inhibitors are open circles) interacting with a viral envelope containing the receptors of the 
inhibitor (grey part-circle is the viral envelope, white open half-circles are receptors, dotted lines 
indicate a binding interaction). Attaching multiple copies of the inhibitor to a polymeric chain 
can result in a multivalent and hence much stronger interaction with the viral receptors.  The 
bottom panel (B) depicts a monovalent interaction of parent inhibitor molecules with a viral 
receptor. In this case, the individual inhibitor molecules act independently of each other in 
binding to their receptors and hence do not benefit from entropically enhanced binding (i.e., from 
multivalency).   
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Table 1. IC50 values for both small molecules and their polymer-attached derivatives 
against the Wuhan strain of influenza A virus.  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
 
	  
 
 
 
 
a The plaque reduction assay experiments were run at least in triplicate; the calculated mean and 
standard deviation values are presented in the table. The IC50 values are expressed based on the 
concentration of the small-molecule inhibitor. The IC50 value of bare poly-L-glutamate was 
found to exceed 1 mM and thus should not appreciably contribute to the extent of inhibition. 
	  
Inhibitor IC50 (µM) a 
1 4.7 ± 1.5 
2a 0.40 ± 0.20 
2b 0.87 ± 0.14 
3 0.020 ± 0.006 
4 95 ± 22 
5a 13 ± 7.2 
5b 13 ± 2.7 
6 2.5 ± 1.6 
7 >100 
8 33 ± 7.0 
9 0.72 ± 0.21 
10 5.7 ± 1.7 
11 18 ± 10 
12 0.11 ± 0.070 
13 5.7 ± 0.70 
14 0.18 ± 0.010 
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Table 2. IC50 values for both small molecules and their polymer-attached derivatives 
against the Puerto Rico and turkey strains of influenza A virus.  
	  
       Inhibitor                                           IC50 (µM)a 
	   Puerto Rico 	   turkey	  
1 13 ± 1.6 4.7 ± 1.6 
3 140 ± 45 84 ± 23 
7 >100 >100 
9 99 ± 16 100 ±5 
10 14 ± 1.6 17 ± 1 
12 150 ± 10 53 ± 20 
13 14 ± 1.0 5.3 ± 2.3 
14b 120 ± 19 >298 
 
a The plaque reduction assay experiments were run at least in triplicate; the calculated mean and 
standard deviation values are presented in the table. The IC50 values are expressed based on the 
concentration of the small-molecule inhibitor. The IC50 values for compounds 4 and 6 exceeded 
170 µM for both viral strains. Thus they were not included in this table because no definitive 
conclusions concerning the effect of attachment to the polymer can be made.	  bAll polymer 
conjugates characterized in this table contain the nine-atom spacer arm, except for 14 which 
comprises 13 conjugated directly to poly-L-glutamate.	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Table 3. IC50 values for compounds 10, 12 and 16 against three influenza A virus strains 
	  
Inhibitor  IC50 (µM)a  
 Wuhan  Puerto Rico  turkey 
10 5.7 ± 1.7 14 ± 1.6 17 ± 1 
12 0.11 ± 0.070 150 ± 10 53 ± 20 
16 45 ± 8 >100b >100b 
 
 a The plaque reduction assay experiments were run at least in triplicate; the calculated mean and 
standard deviation values are presented in the table. The IC50 values are expressed based on the 
concentration of the small-molecule inhibitor. b Although the IC50 values for the turkey and 
Puerto Rico strains could not be conclusively determined because the 50% cell cytotoxicity 
concentration (CC50) for 16 only slightly exceeded 100 µM, there was a visible reduction in 
plaques upon incubation with 90 µM of 16.	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Table 4. Comparison of IC50 values for inhibitors conjugated to polymers of varying 
degrees of backbone charge against the Wuhan and turkey strains of influenza A virus. 
	  
       Inhibitor                                           IC50 (µM)a 
	   Wuhan 	   turkey 	  
12 0.11 ± 0.070 53 ± 20 
17 0.12 ± 0.061 7.4 ± 3.9 
18 0.15 ± 0.035 35 ± 9.0 
	  
a The plaque reduction assay experiments were run at least in triplicate; the calculated mean and 
standard deviation values are presented in the table. The IC50 values are expressed based on the 
concentration of the small-molecule inhibitor. 
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